The emerging genomic landscape of endometrial cancer.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Clinical Chemistry

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1373/clinchem.2013.205740PMID 24170611PMCID PMC4128551
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Advances in the Management of Recurrent Endometrial Cancer

  2015cited by this paper
• Mutational heterogeneity in cancer and the search for new cancer genes

  2014cited by this paper
• Mutational heterogeneity in cancer and the search for new cancer genes

  2014cited by this paper
• DNA polymerase ɛ and δ exonuclease domain mutations in endometrial cancer

  2013cited by this paper
• Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas

  2013cited by this paper
• High‐grade endometrial carcinomas – strategies for typing

  2013cited by this paper
• Evaluation of DNA from the Papanicolaou Test to Detect Ovarian and Endometrial Cancers

  2013cited by this paper
• Integrated genomic characterization of endometrial carcinoma

  2013cited by this paper
• Disparities in uterine cancer epidemiology, treatment, and survival among African Americans in the United States.

  2013cited by this paper
• Type I and II endometrial cancers: have they different risk factors?

  2013cited by this paper
• Molecular pathogenesis of endometrial cancers in patients with Lynch syndrome

  2013cited by this paper
• Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations, TP53 and microsatellite instability in endometrial cancer

  2013cited by this paper
• Clinicopathologic analysis of loss of AT-rich interactive domain 1A expression in endometrial cancer.

  2013cited by this paper
• Mutational heterogeneity in cancer and the search for new cancer genes

  2013cited by this paper
• The incidence of endometrial cancer in women with BRCA1 and BRCA2 mutations: an international prospective cohort study.

  2013cited by this paper
• Poor Interobserver Reproducibility in the Diagnosis of High-grade Endometrial Carcinoma

  2013cited by this paper
• Mismatch repair status and clinical outcome in endometrial cancer: a systematic review and meta-analysis.

  2013cited by this paper
• ARID1A loss is prevalent in endometrial hyperplasia with atypia and low-grade endometrioid carcinomas

  2013cited by this paper
• Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma

  2013cited by this paper
• Frequent mutations in the RPL22 gene and its clinical and functional implications.

  2013cited by this paper
• Abstract 3293: p53 suppresses type II endometrial carcinomas in mice and governs endometrial tumour aggressiveness in humans

  2012cited by this paper
• Genome-Wide Association Study Identifies a Possible Susceptibility Locus for Endometrial Cancer

  2012cited by this paper
• Endometrial serous carcinoma (uterine papillary serous carcinoma): precancerous lesions and the theoretical promise of a preventive approach.

  2012cited by this paper
• The PI3K/AKT/mTOR Pathway as a Therapeutic Target in Endometrial Cancer

  2012cited by this paper
• Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes

  2012cited by this paper
• The genomics and genetics of endometrial cancer.

  2012cited by this paper
• FGFR2 Point Mutations in 466 Endometrioid Endometrial Tumors: Relationship with MSI, KRAS, PIK3CA, CTNNB1 Mutations and Clinicopathological Features

  2012cited by this paper
• Diagnosis and treatment of sarcoma of the uterus. A review

  2012cited by this paper
• Markers for individualised therapy in endometrial carcinoma.

  2012cited by this paper
• Uterine papillary serous cancer: a review of the literature.

  2012cited by this paper
• Development of targeted therapy in uterine serous carcinoma, a biologically aggressive variant of endometrial cancer

  2012cited by this paper
• Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer

  2012cited by this paper
• Molecular Profile of Grade 3 Endometrioid Endometrial Carcinoma: Is it a Type I or Type II Endometrial Carcinoma?

  2012cited by this paper
• Lifetime Cancer Risks in Individuals with Germline PTEN Mutations

  2012cited by this paper
• Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses.

  2012cited by this paper
• Inactivation of ribosomal protein L22 promotes transformation by induction of the stemness factor, Lin28B.

  2012cited by this paper
• Use of mutation profiles to refine the classification of endometrial carcinomas

  2012cited by this paper
• Tumors of the uterine corpus

  2012cited by this paper
• Germline mutations in the proof-reading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas

  2012cited by this paper
• p53 suppresses type II endometrial carcinomas in mice and governs endometrial tumour aggressiveness in humans

  2012cited by this paper
• Uterine Papillary Serous Carcinoma

  2011cited by this paper
• PIK3R1 (p85α) is somatically mutated at high frequency in primary endometrial cancer.

  2011cited by this paper
• High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.

  2011cited by this paper
• Improved classification of breast cancer by analysis of genetic alterations and gene expression profiling

  2011cited by this paper
• Comparative Performance of the 2009 International Federation of Gynecology and Obstetrics' Staging System for Uterine Corpus Cancer.

  2011cited by this paper
• Emerging therapeutic targets in endometrial cancer

  2011cited by this paper
• A Unique Spectrum of Somatic PIK3CA (p110α) Mutations Within Primary Endometrial Carcinomas

  2011cited by this paper
• Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

  2010cited by this paper
• High-Grade Endometrial Carcinoma: Serous and Grade 3 Endometrioid Carcinomas Have Different Immunophenotypes and Outcomes

  2010cited by this paper
• Endometrial carcinoma: controversies in histopathological assessment of grade and tumour cell type

  2010cited by this paper
• Comparative Performance of the 2009 International Federation of Gynecology and Obstetrics' Staging System for Uterine Corpus Cancer

  2010cited by this paper
• Utility of p16 Expression for Distinction of Uterine Serous Carcinomas From Endometrial Endometrioid and Endocervical Adenocarcinomas: Immunohistochemical Analysis of 201 Cases

  2009cited by this paper
• BRCA Germline Mutations in Women With Uterine Serous Carcinoma-Still a Debate

  2009cited by this paper
• Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.

  2008cited by this paper
• DNA polymerase epsilon: a polymerase of unusual size (and complexity).

  2008cited by this paper
• Microsatellite instability and epigenetic inactivation of MLH1 and outcome of patients with endometrial carcinomas of the endometrioid type.

  2007cited by this paper
• A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.

  2007cited by this paper
• Molecular genetic defects in endometrial carcinomas: microsatellite instability, PTEN and beta-catenin (CTNNB1) genes mutations

  2007cited by this paper
• Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes

  2007cited by this paper
• Tumors of the Uterine Corpus

  2007cited by this paper
• Microsatellite Instability in Endometrioid Type Endometrial Adenocarcinoma is Associated With Poor Prognostic Indicators

  2007cited by this paper
• Clinicopathologic significance of defective DNA mismatch repair in endometrial carcinoma.

  2006cited by this paper
• High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma.

  2005cited by this paper
• Serous Endometrial Cancers That Mimic Endometrioid Adenocarcinomas: A Clinicopathologic and Immunohistochemical Study of a Group of Problematic Cases

  2004cited by this paper
• Molecular alterations associated with cyclin d1 overexpression in endometrial cancer

  2004cited by this paper
• Prevalence of defective DNA mismatch repair and MSH6 mutation in an unselected series of endometrial cancers

  2003cited by this paper
• Pathology and Genetics of Tumours of the Breast and Female Genital Organs

  2003cited by this paper
• CTNNB1 mutations and β-catenin expression in endometrial carcinomas

  2002cited by this paper
• β-Catenin and E-Cadherin Expression Patterns in High-Grade Endometrial Carcinoma Are Associated with Histological Subtype

  2002cited by this paper
• CTNNB1 mutations and beta-catenin expression in endometrial carcinomas.

  2002cited by this paper
• MLH1 promoter methylation and gene silencing is the primary cause of microsatellite instability in sporadic endometrial cancers.

  1999cited by this paper
• hMLH1 promoter hypermethylation is an early event in human endometrial tumorigenesis.

  1999cited by this paper
• Distinct chromosomal imbalances in uterine serous and endometrioid carcinomas.

  1998cited by this paper
• PTEN/MMAC1 mutations in endometrial cancers.

  1997cited by this paper
• p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis.

  1997cited by this paper
• p53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis.

  1995cited by this paper
• Uterine papillary serous adenocarcinoma. A 10‐case study of p53 and c‐erbB‐2 expression and DNA content

  1994cited by this paper
• The tumour spectrum in hereditary non‐polyposis colorectal cancer: A study of 24 kindreds in the netherlands

  1990cited by this paper
• DNA content as a prognostic factor in endometrial carcinoma

  1990cited by this paper
• Epidemiology of cancer of the endometrium.

  1982cited by this paper
• Hereditary factors in cancer. Study of two large midwestern kindreds.

  1966cited by this paper

• Advances in cancer genomics and precision oncology

  2025cites this paper
• Genomic Landscapes of Endometrioid and Mucinous Ovarian Cancers and Morphologically Similar Tumor Types

  2025cites this paper
• Tailoring Endometrial Cancer Treatment Based on Molecular Pathology: Current Status and Possible Impacts on Systemic and Local Treatment

  2024cites this paper
• Comprehensive molecular characterization of early stage grade 3 endometrioid endometrial adenocarcinoma.

  2024cites this paper
• The ErbB Signaling Network and Its Potential Role in Endometrial Cancer

  2023cites this paper
• Impaired dNKAP function drives genome instability and tumorigenic growth in Drosophila epithelia

  2023cites this paper
• A randomized phase 2 study of sapanisertib in combination with paclitaxel versus paclitaxel alone in women with advanced, recurrent, or persistent endometrial cancer

  2023cites this paper
• Genomic profile of Chinese patients with endometrial carcinoma

  2023cites this paper
• Clinical significance of SPOP and APC gene alterations in colorectal cancer in Indian population

  2023cites this paper
• Novel Insights into Molecular Mechanisms of Endometrial Diseases

  2023cites this paper
• Role of Genomic and Molecular Biology in the Modulation of the Treatment of Endometrial Cancer: Narrative Review and Perspectives

  2023cites this paper
• Intratumor genetic heterogeneity and clonal evolution to decode endometrial cancer progression

  2022cites this paper
• Integrated Bioinformatics Analysis of Serine Racemase as an Independent Prognostic Biomarker in Endometrial Cancer

  2022cites this paper
• High incidence of PI3K pathway gene mutations in South Indian cervical cancers.

  2022cites this paper
• Clinicopathologic significance of DNA mismatch repair protein status in endometrial cancer.

  2022cites this paper
• Emerging Treatment Options for Advanced or Recurrent Endometrial Cancer

  2022cites this paper
• PP2A and E3 ubiquitin ligase deficiencies: Seminal biological drivers in endometrial cancer.

  2021cites this paper
• Speckle-type POZ adaptor protein (SPOP) and its role in cancer

  2021cites this paper
• A clinical case of successful treatment of a giant serous endometrial carcinoma imitating ovarian cancer

  2021cites this paper
• Speckle-type POZ adaptor protein (SPOP) and its role in cancer

  2021cites this paper
• Endometrial cancer from early to advanced-stage disease: an update for radiologists

  2021cites this paper
• Research progress of PARP inhibitor monotherapy and combination therapy for endometrial cancer.

  2021cites this paper
• Immunotherapy in endometrial cancer: rationale, practice and perspectives

  2021cites this paper
• A 73-gene proliferative transcriptomic signature predicts uterine serous carcinoma patient survival and response to primary therapy.

  2020cites this paper
• Molecular Classification and Emerging Targeted Therapy in Endometrial Cancer

  2020cites this paper
• Recent Advances in Endometrial Cancer

  2020cites this paper
• Analysis of Expression Data Using Unsupervised Techniques

  2020cites this paper
• Immunohistochemical Expression of Cyclin D1 and PIN1 in Endometrial Carcinoma

  2020influential citation
• Identification of Interleukin-9 Producing Immune Cells in Endometrial Carcinoma and Establishment of a Prognostic Nomogram

  2020cites this paper
• Immunotherapy in Endometrial Cancer: An Evolving Therapeutic Modality

  2020cites this paper
• PARP Inhibitors in Endometrial Cancer: Current Status and Perspectives

  2020cites this paper
• PARP Inhibitors in Endometrial Cancer: Current Status and Perspectives

  2020cites this paper
• Decreased secretoglobin family 2A member 1expression is associated with poor outcomes in endometrial cancer

  2020cites this paper
• Immunotherapy in gynecological cancers: where are we?

  2020cites this paper
• Intratumour heterogeneity in endometrial serous carcinoma assessed by targeted sequencing and multiplex ligation‐dependent probe amplification: a descriptive study

  2020cites this paper
• SWATH-MS Analysis of FFPE Tissues Identifies Stathmin as a Potential Marker of Endometrial Cancer in Patients Exposed to Tamoxifen.

  2020cites this paper
• The mutational landscape of normal human endometrial epithelium

  2020cites this paper
• PARP Inhibitors in Endometrial Cancer: Current Status and Perspectives

  2020cites this paper
• Epigenetic alterations in female urogenital organs cancer: Premise, properties, and perspectives

  2020cites this paper
• Pathogenesis and Clinical Management of Uterine Serous Carcinoma

  2020cites this paper
• The emerging role of SPOP protein in tumorigenesis and cancer therapy

  2020cites this paper
• A gene expression assay for simultaneous measurement of microsatellite instability and anti-tumor immune activity

  2019cites this paper
• Genome-wide characterization of aberrant DNA methylation patterns and the potential clinical implications in patients with endometrial cancer.

  2019cites this paper
• Investigational PI3K/AKT/mTOR inhibitors in development for endometrial cancer

  2019cites this paper
• PIK3CA in cancer: The past 30 years.

  2019cites this paper
• Potential Role for a Panel of Immunohistochemical Markers in the Management of Endometrial Carcinoma

  2019cites this paper
• Immune check-point in endometrial cancer

  2019cites this paper
• Role of Cyclin-Dependent Kinase Inhibitors in Endometrial Cancer

  2019influential citation
• High risk endometrial cancer: clues towards a revision of the therapeutic paradigm.

  2019cites this paper
• Clinical Features of Recurrence in Patients Without Residual Tumour in Endometrial Cancer

  2019cites this paper
• Endometrial Cancer Genetic Classification and Its Clinical Application

  2019cites this paper
• Classification of Endometrial Carcinoma: New Perspectives Beyond Morphology.

  2019cites this paper
• Computational Prediction of Tumor-Specific Antigens as Potential Vaccine Candidates against Germ-line Mutations in Endometrial Cancer

  2019cites this paper
• Targeting Immune-Related Biological Processes in Solid Tumors: We do Need Biomarkers

  2019cites this paper
• Primary Age-Related Tauopathy

  2019cites this paper
• A Comparison of GATA3, TTF1, CD10, and Calretinin in Identifying Mesonephric and Mesonephric-like Carcinomas of the Gynecologic Tract

  2018cites this paper
• Pathology Consultation for the Gynecologic Oncologist: What the Surgeon Wants to Know.

  2018cites this paper
• Overexpression of HOMER2 predicts better outcome in low-grade endometrioid endometrial adenocarcinoma.

  2018cites this paper
• Clinical Outcome of Patients With High-Risk Endometrial Carcinoma After Treatment With Chemotherapy Only

  2018cites this paper
• Uterine function in the mouse requires speckle-type poz protein†

  2018cites this paper
• Functional Role of Protein Kinase C Alpha in Endometrial Carcinogenesis

  2018cites this paper
• The mutational landscape of normal human endometrial epithelium

  2018cites this paper
• Class I Phosphoinositide 3-Kinase PIK3CA/p110α and PIK3CB/p110β Isoforms in Endometrial Cancer

  2018cites this paper
• Discordant loss of mismatch repair proteins in advanced endometrial endometrioid carcinoma compared to paired primary uterine tumors.

  2018cites this paper
• m6A mRNA methylation regulates AKT activity to promote the proliferation and tumorigenicity of endometrial cancer

  2018cites this paper
• Pathology and molecular pathology of uterine and ovarian cancers

  2017cites this paper
• Mucinous Adenocarcinoma of the Endometrium

  2017cites this paper
• [Current prerequisites for a molecular genetic classification of endometrial cancer].

  2017cites this paper
• Genome-wide analysis of gynecologic cancer: The Cancer Genome Atlas in ovarian and endometrial cancer.

  2017cites this paper
• New use of microsatellite instability analysis in endometrial cancer

  2017cites this paper
• Checkpoint inhibitors in endometrial cancer: preclinical rationale and clinical activity

  2017cites this paper
• Aplicabilidad de la RT-PCR a tiempo real a partir de tejido fijado en formol e incluido en parafina a la búsqueda de perfiles de expresión génica con valor pronóstico en cáncer de endometrio

  2017cites this paper
• Pathology, Genomics, and Treatment of Endometrial Cancer

  2017cites this paper
• CD8, FoxP3, and CD45RO+ Lymphocytic Infiltrates in Type I and Type II Endometrial Cancers in African American and European American Females

  2017cites this paper
• Biological markers with potential clinical value in endometrial cancer - review of the literature.

  2017cites this paper
• Precision Medicine in Gynecology and Obstetrics

  2017influential citation
• CXCL12/CXCR4 axis induces proliferation and invasion in human endometrial cancer.

  2016cites this paper
• An update of the classical Bokhman's dualistic model of endometrial cancer

  2016cites this paper
• Molecular Pathology: Predictive, Prognostic, and Diagnostic Markers in Uterine Tumors.

  2016cites this paper
• Robotic-assisted laparoscopic hysterectomy for women with endometrial cancer - complications, women´s experiences, quality of life and a health economic evaluation.

  2016influential citation
• Präkanzerosen und Malignome des Endometriums

  2016cites this paper
• A Multi-Step miRNA-mRNA Regulatory Network Construction Approach Identifies Gene Signatures Associated with Endometrioid Endometrial Carcinoma

  2016cites this paper
• Surgery for early stage endometrial carcinoma in the obese patient

  2016cites this paper
• Tumor genotype and immune microenvironment in POLE-ultramutated and MSI-hypermutated Endometrial Cancers: New candidates for checkpoint blockade immunotherapy?

  2016cites this paper
• Integrative bioinformatic analyses of an oncogenomic profile reveal the biology of endometrial cancer and guide drug discovery

  2015cites this paper
• Clinicopathological Features in Endometrial Carcinoma with Mismatch Repair Deficiency among Chinese Women Younger than 50 Years of Age

  2015cites this paper
• Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative

  2015cites this paper
• Patterns of CTCF and ZFHX3 Mutation and Associated Outcomes in Endometrial Cancer.

  2015cites this paper
• Immunohistochemical study of endometrial high‐grade endometrioid carcinoma with or without a concurrent low‐grade component: implications for pathogenetic and survival differences

  2015cites this paper
• Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations

  2015cites this paper
• Loss of Mismatch Repair Protein Expression in Unselected Endometrial Adenocarcinoma Precursor Lesions

  2015cites this paper
• Cytokine Stimulation of MUC4 Expression in Human Female Reproductive Tissue Carcinoma Cell Lines and Endometrial Cancer

  2015cites this paper
• Endometrial cancer-associated mutants of SPOP are defective in regulating estrogen receptor-α protein turnover

  2015cites this paper
• ATM may be a protective factor in endometrial carcinogenesis with the progesterone pathway

  2015cites this paper
• What's different about women's health?

  2014cites this paper
• Reversible inhibition of lysine specific demethylase 1 is a novel anti-tumor strategy for poorly differentiated endometrial carcinoma

  2014cites this paper
• Activation of PI3K/Akt/mTOR pathway and dual inhibitors of PI3K and mTOR in endometrial cancer.

  2014cites this paper
• Seminars in Cancer Biology

  year unknowncites this paper